search
Back to results

THC Memory & Reward Learning Pilot

Primary Purpose

Marijuana, THC, Cannabis

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Marijuana, Hash, THC, or Grass
Placebo
Sponsored by
Hartford Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Marijuana focused on measuring Cannabis, THC, Marijuana, MRI, Memory, Learning

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18-55 years old
  • Right handed
  • CNB use within past 2 years and felt "high" when used
  • Able to read, speak, and understand English
  • Able and willing to provide written informed consent, and willing to commit to study protocol.

Exclusion Criteria:

  • Current marijuana tolerance, desire to cut down, or cravings to sue during periods of abstinence.
  • Strongly left-handed
  • Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment
  • History of adverse effects with CNB
  • CNB users who are abstaining
  • Report of any psychotic disorder in a first degree relative
  • IQ < 80 on the Wechsler Abbreviated Scale of Intelligence
  • Inability to comprehend written instructions using the WRAT-4 reading achievement test
  • Pregnant, breastfeeding, and ineffective birth control methods.
  • Unable or unsafe to have an MRI
  • Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy
  • History of head trauma with loss of consciousness > 30 minutes or concussion lasting 30 days.
  • Focal brain lesion seen on structural MRI
  • Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome).
  • Anyone deemed unsafe to study personnel for any reason

Sites / Locations

  • Hartford HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

High Dose THC

Placebo THC

Arm Description

Participants will receive high dose THC.

Participants will receive placebo THC.

Outcomes

Primary Outcome Measures

Marijuana induced performance changes on fMRI Multi-Stage Decision Making (MSDM) Task.
The MSDM is a reinforcement learning paradigm that quantifies the degree to which subjects can integrate recent trial-to-trial information about a stimulus' likelihood of reward with acquired knowledge about whether some choices generally lead to disadvantageous outcomes vs. others that more often lead to reward.
Marijuana induced performance changes on Relational and Item Specific Coding (RISE) fMRI Task.
The RISE task is a hippocampal-dependent learning paradigm that assesses declarative memory.
Marijuana induced performance changes on fMRI Treadway/Effort Reward Task.
The Treadway Effort/Reward Task independently measures the neural responses to two dimensions of a cost/benefit decision: the effort required and the magnitude of reward.
Marijuana induced performance changes on fMRI Monetary Incentive Delay (MID) Task.
The MID task probes the brain's reward system to assess the anticipation and receipt of rewards or punishment.

Secondary Outcome Measures

Full Information

First Posted
October 28, 2021
Last Updated
August 4, 2022
Sponsor
Hartford Hospital
Collaborators
Yale University
search

1. Study Identification

Unique Protocol Identification Number
NCT05116527
Brief Title
THC Memory & Reward Learning Pilot
Official Title
Pilot fMRI Studies of THC Effects on Memory and Reward Learning
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 7, 2022 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
February 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hartford Hospital
Collaborators
Yale University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Tetrahydrocannabidiol (THC) is the psychoactive chemical in cannabis that makes people high. This study aims to dissect acute impairment of various forms of memory and learning by THC in cannabis compared to placebo. Impairment will be assessed via a short cognitive test battery and then subjects will complete four tasks in the fMRI scanner.
Detailed Description
The protocol below is designed to begin dissecting acute impairment of various forms of memory and learning by THC in cannabis compared to placebo, in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design in young to middle-aged adults. The purpose of these experiments is to gather important pilot data to demonstrate proof of principle for a planned NIDA submission of a P50 center application that will examine cannabis's differential effects on the neural circuit underpinnings these various cognitive domains across the lifespan in much more detail. In other words, these pilot data will show NIDA that the investigators' methods and approaches work and are suitable for use in their proposed center grant application. Unlike in the planned P50, in these small-scale pilot studies the investigators are only concerned with comparing these disrupting effects using a single dose of THC versus placebo, without exploration of age, sleep, or sex-related differential effects or of different dose-related effects. Tasks tapping each of the major cognitive memory-related domains will be performed in the MRI scanner, to reveal the relevant underlying circuitry and its disruption by drug using functional MRI. Although each of the fMRI tasks is already implemented in the investigators' lab in other contexts, the investigators have never studied alteration of the fMRI tasks by THC. Neither have other investigators elsewhere used this approach. It is also important to point out that the dose of active THC to be administered is the same as that already used safely in the investigators' IRB-approved driving studies, one which subjects state subjectively (a blind to actual dose information) makes them feel moderately intoxicated, and similar to the amount that they would consume themselves recreationally. The study will consist of 3 days (screening visit and 2 dose days). In a randomized, counterbalanced, double-blind study, investigators will administer high THC marijuana or placebo marijuana using paced inhalation through a vaporizer. Following administration, subjects will provide subjectively-rated CNB intoxication using a verbal analog scale, a short cognitive test battery, then complete 4 fMRI paradigms within ~1.5 hours: a) MSDM task, b) MID task, c) RISE task, and d) Treadway Effort/Reward task. These tests will be counterbalanced across subjects and sessions to minimize order and fatigue effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Marijuana, THC, Cannabis
Keywords
Cannabis, THC, Marijuana, MRI, Memory, Learning

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Model Description
All subjects will receive both study drug and placebo.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
High Dose THC
Arm Type
Experimental
Arm Description
Participants will receive high dose THC.
Arm Title
Placebo THC
Arm Type
Experimental
Arm Description
Participants will receive placebo THC.
Intervention Type
Drug
Intervention Name(s)
Marijuana, Hash, THC, or Grass
Other Intervention Name(s)
Marijuana, THC
Intervention Description
Marijuana flower with a high THC content
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo THC - marijuana flower with no THC content
Primary Outcome Measure Information:
Title
Marijuana induced performance changes on fMRI Multi-Stage Decision Making (MSDM) Task.
Description
The MSDM is a reinforcement learning paradigm that quantifies the degree to which subjects can integrate recent trial-to-trial information about a stimulus' likelihood of reward with acquired knowledge about whether some choices generally lead to disadvantageous outcomes vs. others that more often lead to reward.
Time Frame
Baseline and post drug administration at 10 minutes.
Title
Marijuana induced performance changes on Relational and Item Specific Coding (RISE) fMRI Task.
Description
The RISE task is a hippocampal-dependent learning paradigm that assesses declarative memory.
Time Frame
Baseline and post drug administration at 10 minutes.
Title
Marijuana induced performance changes on fMRI Treadway/Effort Reward Task.
Description
The Treadway Effort/Reward Task independently measures the neural responses to two dimensions of a cost/benefit decision: the effort required and the magnitude of reward.
Time Frame
Baseline and post drug administration at 10 minutes.
Title
Marijuana induced performance changes on fMRI Monetary Incentive Delay (MID) Task.
Description
The MID task probes the brain's reward system to assess the anticipation and receipt of rewards or punishment.
Time Frame
Baseline and post drug administration at 10 minutes.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18-55 years old Right handed CNB use within past 2 years and felt "high" when used Able to read, speak, and understand English Able and willing to provide written informed consent, and willing to commit to study protocol. Exclusion Criteria: Current marijuana tolerance, desire to cut down, or cravings to sue during periods of abstinence. Strongly left-handed Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment History of adverse effects with CNB CNB users who are abstaining Report of any psychotic disorder in a first degree relative IQ < 80 on the Wechsler Abbreviated Scale of Intelligence Inability to comprehend written instructions using the WRAT-4 reading achievement test Pregnant, breastfeeding, and ineffective birth control methods. Unable or unsafe to have an MRI Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy History of head trauma with loss of consciousness > 30 minutes or concussion lasting 30 days. Focal brain lesion seen on structural MRI Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome). Anyone deemed unsafe to study personnel for any reason
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Suyash Adhikari, B.S
Phone
860-545-7106
Email
Suyash.Adhikari@hhchealth.org
First Name & Middle Initial & Last Name or Official Title & Degree
Diana King, B.A
Phone
860-545-7563
Email
Diana.King@hhchealth.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Godfrey Pearlson, M.D
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hartford Hospital
City
Hartford
State/Province
Connecticut
ZIP/Postal Code
06102
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diana King, B.A
Phone
860-545-7563
Email
Diana.King@hhchealth.org
First Name & Middle Initial & Last Name & Degree
Suyash Adhikari, B.S
Phone
860-545-7106
Email
Suyash.Adhikari@hhchealth.org

12. IPD Sharing Statement

Learn more about this trial

THC Memory & Reward Learning Pilot

We'll reach out to this number within 24 hrs